Cargando…
Use of psycho‐oncological services by prostate cancer patients: A multilevel analysis
BACKGROUND: Cancer patients often suffer from psychological distress. Psycho‐oncological services (POS) have been established in some health care systems in order to address such issues. This study aims to identify patient and center characteristics that elucidate the use of POS by patients in prost...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7286449/ https://www.ncbi.nlm.nih.gov/pubmed/32233081 http://dx.doi.org/10.1002/cam4.2999 |
_version_ | 1783544878337097728 |
---|---|
author | Breidenbach, Clara Roth, Rebecca Ansmann, Lena Wesselmann, Simone Dieng, Sebastian Carl, Ernst‐Günther Feick, Günter Oesterle, Alisa Bach, Peter Beyer, Burkhard Borowitz, Rainer Erdmann, Jörg Kunath, Frank Oostdam, Simba‐Joshua Tsaur, Igor Zengerling, Friedemann Kowalski, Christoph |
author_facet | Breidenbach, Clara Roth, Rebecca Ansmann, Lena Wesselmann, Simone Dieng, Sebastian Carl, Ernst‐Günther Feick, Günter Oesterle, Alisa Bach, Peter Beyer, Burkhard Borowitz, Rainer Erdmann, Jörg Kunath, Frank Oostdam, Simba‐Joshua Tsaur, Igor Zengerling, Friedemann Kowalski, Christoph |
author_sort | Breidenbach, Clara |
collection | PubMed |
description | BACKGROUND: Cancer patients often suffer from psychological distress. Psycho‐oncological services (POS) have been established in some health care systems in order to address such issues. This study aims to identify patient and center characteristics that elucidate the use of POS by patients in prostate cancer centers (PCCs). METHODS: Center‐reported certification and patient survey data from 3094 patients in 44 certified PCCs in Germany were gathered in the observational study (Prostate Cancer Outcomes). A multilevel analysis was conducted. RESULTS: Model 1 showed that utilization of POS in PCCs is associated with patients’ age (OR = 0.98; 95%‐CI = 0.96‐0.99; P < .001), number of comorbidities (1‐2 vs 0, OR = 1.27; 95%‐CI = 1.00‐1.60; P=.048), disease staging (localized high‐risk vs localized intermediate risk, OR = 1.41; 95%‐CI = 1.14‐1.74; P < .001), receiving androgen deprivation therapy before study inclusion (OR = 0.19; 95%‐CI = 0.10‐0.34; P < .001), and hospital teaching status (university vs academic, OR = 0.09; 95%‐CI = 0.02‐0.55; P = .009). Model 2 additionally includes information on treatment after study inclusion and shows that after inclusion, patients who receive primary radiotherapy (OR = 0.05; 95%‐CI = 0.03‐0.10; P < .001) or undergo active surveillance/watchful waiting (OR = 0.06; 95%‐CI = 0.02‐0.15; P < .001) are less likely to utilize POS than patients who undergo radical prostatectomy. Disease staging (localized high‐risk vs localized intermediate risk, OR = 1.31; 95%‐CI = 1.05‐1.62; P = .02) and teaching status (university vs academic, OR = 0.08; 95%‐CI = 0.01‐0.65; P = .02) are also significant predictors for POS use. The second model did not identify any other significant patient characteristics. CONCLUSIONS: Future research should explore the role of institutional teaching status and whether associations with therapy after study inclusion are due to treatment effects – for example, less need following radiotherapy – or because access to POS is more difficult for those receiving radiotherapy. |
format | Online Article Text |
id | pubmed-7286449 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-72864492020-06-11 Use of psycho‐oncological services by prostate cancer patients: A multilevel analysis Breidenbach, Clara Roth, Rebecca Ansmann, Lena Wesselmann, Simone Dieng, Sebastian Carl, Ernst‐Günther Feick, Günter Oesterle, Alisa Bach, Peter Beyer, Burkhard Borowitz, Rainer Erdmann, Jörg Kunath, Frank Oostdam, Simba‐Joshua Tsaur, Igor Zengerling, Friedemann Kowalski, Christoph Cancer Med Clinical Cancer Research BACKGROUND: Cancer patients often suffer from psychological distress. Psycho‐oncological services (POS) have been established in some health care systems in order to address such issues. This study aims to identify patient and center characteristics that elucidate the use of POS by patients in prostate cancer centers (PCCs). METHODS: Center‐reported certification and patient survey data from 3094 patients in 44 certified PCCs in Germany were gathered in the observational study (Prostate Cancer Outcomes). A multilevel analysis was conducted. RESULTS: Model 1 showed that utilization of POS in PCCs is associated with patients’ age (OR = 0.98; 95%‐CI = 0.96‐0.99; P < .001), number of comorbidities (1‐2 vs 0, OR = 1.27; 95%‐CI = 1.00‐1.60; P=.048), disease staging (localized high‐risk vs localized intermediate risk, OR = 1.41; 95%‐CI = 1.14‐1.74; P < .001), receiving androgen deprivation therapy before study inclusion (OR = 0.19; 95%‐CI = 0.10‐0.34; P < .001), and hospital teaching status (university vs academic, OR = 0.09; 95%‐CI = 0.02‐0.55; P = .009). Model 2 additionally includes information on treatment after study inclusion and shows that after inclusion, patients who receive primary radiotherapy (OR = 0.05; 95%‐CI = 0.03‐0.10; P < .001) or undergo active surveillance/watchful waiting (OR = 0.06; 95%‐CI = 0.02‐0.15; P < .001) are less likely to utilize POS than patients who undergo radical prostatectomy. Disease staging (localized high‐risk vs localized intermediate risk, OR = 1.31; 95%‐CI = 1.05‐1.62; P = .02) and teaching status (university vs academic, OR = 0.08; 95%‐CI = 0.01‐0.65; P = .02) are also significant predictors for POS use. The second model did not identify any other significant patient characteristics. CONCLUSIONS: Future research should explore the role of institutional teaching status and whether associations with therapy after study inclusion are due to treatment effects – for example, less need following radiotherapy – or because access to POS is more difficult for those receiving radiotherapy. John Wiley and Sons Inc. 2020-03-31 /pmc/articles/PMC7286449/ /pubmed/32233081 http://dx.doi.org/10.1002/cam4.2999 Text en © 2020 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Clinical Cancer Research Breidenbach, Clara Roth, Rebecca Ansmann, Lena Wesselmann, Simone Dieng, Sebastian Carl, Ernst‐Günther Feick, Günter Oesterle, Alisa Bach, Peter Beyer, Burkhard Borowitz, Rainer Erdmann, Jörg Kunath, Frank Oostdam, Simba‐Joshua Tsaur, Igor Zengerling, Friedemann Kowalski, Christoph Use of psycho‐oncological services by prostate cancer patients: A multilevel analysis |
title | Use of psycho‐oncological services by prostate cancer patients: A multilevel analysis |
title_full | Use of psycho‐oncological services by prostate cancer patients: A multilevel analysis |
title_fullStr | Use of psycho‐oncological services by prostate cancer patients: A multilevel analysis |
title_full_unstemmed | Use of psycho‐oncological services by prostate cancer patients: A multilevel analysis |
title_short | Use of psycho‐oncological services by prostate cancer patients: A multilevel analysis |
title_sort | use of psycho‐oncological services by prostate cancer patients: a multilevel analysis |
topic | Clinical Cancer Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7286449/ https://www.ncbi.nlm.nih.gov/pubmed/32233081 http://dx.doi.org/10.1002/cam4.2999 |
work_keys_str_mv | AT breidenbachclara useofpsychooncologicalservicesbyprostatecancerpatientsamultilevelanalysis AT rothrebecca useofpsychooncologicalservicesbyprostatecancerpatientsamultilevelanalysis AT ansmannlena useofpsychooncologicalservicesbyprostatecancerpatientsamultilevelanalysis AT wesselmannsimone useofpsychooncologicalservicesbyprostatecancerpatientsamultilevelanalysis AT diengsebastian useofpsychooncologicalservicesbyprostatecancerpatientsamultilevelanalysis AT carlernstgunther useofpsychooncologicalservicesbyprostatecancerpatientsamultilevelanalysis AT feickgunter useofpsychooncologicalservicesbyprostatecancerpatientsamultilevelanalysis AT oesterlealisa useofpsychooncologicalservicesbyprostatecancerpatientsamultilevelanalysis AT bachpeter useofpsychooncologicalservicesbyprostatecancerpatientsamultilevelanalysis AT beyerburkhard useofpsychooncologicalservicesbyprostatecancerpatientsamultilevelanalysis AT borowitzrainer useofpsychooncologicalservicesbyprostatecancerpatientsamultilevelanalysis AT erdmannjorg useofpsychooncologicalservicesbyprostatecancerpatientsamultilevelanalysis AT kunathfrank useofpsychooncologicalservicesbyprostatecancerpatientsamultilevelanalysis AT oostdamsimbajoshua useofpsychooncologicalservicesbyprostatecancerpatientsamultilevelanalysis AT tsaurigor useofpsychooncologicalservicesbyprostatecancerpatientsamultilevelanalysis AT zengerlingfriedemann useofpsychooncologicalservicesbyprostatecancerpatientsamultilevelanalysis AT kowalskichristoph useofpsychooncologicalservicesbyprostatecancerpatientsamultilevelanalysis |